Eculizumab and aHUS: Spotlight on Patient-Centered Care.
作者信息
Rafat Cédric, Luque Yosu
机构信息
Service des Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Paris, France.
Inserm, UMR_S1155, Sorbonne Université, Paris, France.
出版信息
Kidney Int Rep. 2020 Jun 17;5(8):1123-1125. doi: 10.1016/j.ekir.2020.06.007. eCollection 2020 Aug.
Abstract
摘要
相似文献
1
Eculizumab and aHUS: Spotlight on Patient-Centered Care.依库珠单抗与非典型溶血性尿毒症综合征：聚焦以患者为中心的护理。
Kidney Int Rep. 2020 Jun 17;5(8):1123-1125. doi: 10.1016/j.ekir.2020.06.007. eCollection 2020 Aug.
2
Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.接受依库珠单抗维持治疗的患者孕期非典型溶血性尿毒症综合征复发：一例报告
Am J Case Rep. 2019 Oct 4;20:1460-1465. doi: 10.12659/AJCR.916994.
3
Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.依库珠单抗对一名携带CFHR1/CFH杂合基因的非典型溶血尿毒综合征患者进行的三个月间隔治疗
CEN Case Rep. 2019 May;8(2):139-143. doi: 10.1007/s13730-019-00383-7. Epub 2019 Feb 4.
4
Transplantation in pediatric aHUS within the era of eculizumab therapy.儿童抗肾小球基底膜病行肾移植治疗的时代
Pediatr Transplant. 2021 May;25(3):e13914. doi: 10.1111/petr.13914. Epub 2020 Nov 20.
5
Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.使用补体抑制剂依库珠单抗治疗非典型溶血性尿毒症综合征：澳大利亚同情用药队列的经验
Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.
6
Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.补体因子H杂交基因所致血浆置换抵抗性复发性非典型溶血尿毒综合征的依库珠单抗成功治疗7年：病例报告
Transplant Proc. 2018 Apr;50(3):967-970. doi: 10.1016/j.transproceed.2018.02.012.
7
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.治疗偏好和生活质量影响：瑞维鲁单抗与依库珠单抗治疗非典型溶血尿毒症综合征。
J Comp Eff Res. 2023 Sep;12(9):e230036. doi: 10.57264/cer-2023-0036. Epub 2023 Jul 29.
8
Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.病例报告：一例非典型溶血性尿毒症综合征患者中依库珠单抗的可变药代动力学特征。
Front Immunol. 2021 Jan 15;11:612706. doi: 10.3389/fimmu.2020.612706. eCollection 2020.
9
Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.在急性期使用依库珠单抗治疗非典型溶血性尿毒症综合征患儿的实际问题：4例患者的回顾
Nephrology (Carlton). 2018 Jun;23(6):539-545. doi: 10.1111/nep.13054.
10
Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry.全球非典型溶血尿毒综合征（aHUS）注册研究中患者疲劳及其他患者报告结局的功能评估
Kidney Int Rep. 2020 May 19;5(8):1161-1171. doi: 10.1016/j.ekir.2020.05.003. eCollection 2020 Aug.
本文引用的文献
1
Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry.全球非典型溶血尿毒综合征（aHUS）注册研究中患者疲劳及其他患者报告结局的功能评估
Kidney Int Rep. 2020 May 19;5(8):1161-1171. doi: 10.1016/j.ekir.2020.05.003. eCollection 2020 Aug.
2
Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry.依库珠单抗安全性：来自全球非典型溶血性尿毒症综合征注册研究的五年经验
Kidney Int Rep. 2019 Aug 2;4(11):1568-1576. doi: 10.1016/j.ekir.2019.07.016. eCollection 2019 Nov.
3
Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO.依库珠单抗治疗溶血尿毒综合征患者的健康相关生活质量评估：基于 EMPRO 的系统评价
Ren Fail. 2018 Nov;40(1):107-118. doi: 10.1080/0886022X.2018.1427110.
4
Long-term health-related quality of life and psychological adjustment in children after haemolytic-uraemic syndrome.溶血尿毒综合征患儿的长期健康相关生活质量及心理调适
Pediatr Nephrol. 2017 May;32(5):869-878. doi: 10.1007/s00467-016-3569-0. Epub 2016 Dec 23.
5
An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.罕见病患者与行业支持的注册机构之间的创新合作关系：全球非典型溶血性尿毒症综合征注册机构
Orphanet J Rare Dis. 2016 Nov 21;11(1):154. doi: 10.1186/s13023-016-0537-5.
6
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.终端补体抑制剂依库珠单抗治疗成人非典型溶血尿毒综合征：一项单臂、开放标签试验。
Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.
7
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.依库珠单抗对非典型溶血性尿毒症综合征患儿是一种安全有效的治疗方法。
Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.
8
Headache prevalence following recovery from TTP and aHUS.血栓性血小板减少性紫癜（TTP）和非典型溶血性尿毒症综合征（aHUS）康复后的头痛患病率。
Ann Hematol. 2015 Sep;94(9):1473-6. doi: 10.1007/s00277-015-2411-2. Epub 2015 Jun 11.
9
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.依库珠单抗治疗非典型溶血性尿毒症综合征的疗效及安全性：来自2期研究2年延长期的结果
Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4.
Zotero 插件